Matoride XL 18mg

What is Matoride XL

Matoride XL is a prolonged-release formulation of methylphenidate hydrochloride, a central nervous system stimulant used in the management of attention-deficit/hyperactivity disorder (ADHD) Matoride XL 18mg .
Marketed in the UK by Sandoz Limited, it provides once-daily dosing for children and adolescents when non-pharmacological interventions alone are insufficient Matoride XL 18mg .

Key facts

• Active ingredient: Methylphenidate hydrochloride (18 mg, 36 mg, 54 mg strengths)

• Form: Prolonged-release, film-coated oral tablet

• Therapeutic class: CNS stimulant (N06BA04)

• Manufacturer: Sandoz Limited (UK)

• Indication: ADHD in patients ≥6 years old

Pharmacology and mechanism

Matoride XL acts as a norepinephrine- and dopamine-reuptake inhibitor (NDRI).
By blocking presynaptic transporters, it increases the extracellular concentration of these neurotransmitters, particularly in dopamine-rich brain regions such as the prefrontal cortex.
The formulation delivers an initial dose followed by gradual release through an osmotic-controlled system, maintaining therapeutic levels for up to 12 hours .

Clinical use and dosing

Prescribing must begin under a clinician experienced in ADHD management.
The medication forms part of a comprehensive treatment program incorporating educational, psychological, and social measures.
Therapy typically starts at 18 mg once daily in the morning, with weekly titration in 18 mg increments up to a maximum of 54 mg per day.
Tablets must be swallowed whole and never chewed or crushed .